
Spine
High-dose TXA more effective than low-dose TXA and placebo for reducing blood loss in PLIF
Eur Spine J. 2017 Nov;26(11):2851-285772 patients scheduled for posterior lumbar interbody fusion were randomized to either high-dose tranexamic acid, low-dose tranexamic acid, or placebo saline. All patients were treated with an initial bolus prior to incision, followed by continuous infusion for the next 5 hours. Main outcome measures included intraoperative, postoperative, and total blood loss, as well as transfusion rate. Measures of blood loss volume all significantly favoured the high-dose TXA group compared to both the low-dose TXA group and saline group, though no patient in any of the three groups required transfusion. Two cases of venous thromboembolic complication were observed, both occurring in the placebo group.
Unlock the full article
Get unlimited access to OrthoEvidence with a free trial
Start TrialCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or continue reading this full article
Register Now

Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.